| P50 | author | John R. Geddes | Q21094756 |
| P2093 | author name string | A Vasudev | |
| | S Watson | |
| | A H Young | |
| | K Macritchie | |
| P2860 | cites work | Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology | Q35180787 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies | Q36161335 |
| | Oxcarbazepine in the treatment of bipolar and schizoaffective disorders | Q36847238 |
| | Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials | Q36936379 |
| | Role of newer medications for bipolar disorder | Q41033546 |
| | Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine | Q42282901 |
| | Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode | Q44801076 |
| | Hyponatremia from oxcarbazepine and carbamazepine | Q46870344 |
| | Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder. | Q54106227 |
| | A Coefficient of Agreement for Nominal Scales | Q57167717 |
| | A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness | Q71548627 |
| | Oxcarbazepine versus Divalproex Sodium for the Continuing Treatment of Mania | Q80397920 |
| | Tiagabine in the treatment of acute affective episodes in bipolar disorder | Q24244993 |
| | Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials | Q27860735 |
| | Meta-analysis in clinical trials | Q27860779 |
| | Assessing the quality of reports of randomized clinical trials: is blinding necessary? | Q27860973 |
| | Detecting skewness from summary information | Q29620977 |
| | Historical perspectives and natural history of bipolar disorder | Q33920209 |
| | Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders | Q34106678 |
| | Oxcarbazepine in affective and schizoaffective disorders | Q34485128 |
| | A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents | Q34568810 |
| | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. | Q34588960 |
| P433 | issue | 1 | |
| P921 | main subject | bipolar disorder | Q131755 |
| P304 | page(s) | CD005171 | |
| P577 | publication date | 2008-01-23 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Oxcarbazepine in the maintenance treatment of bipolar disorder | |